TherapeuticsMD Inc (TXMD) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “outperform” rating reiterated by analysts at Oppenheimer Holdings, Inc. in a report released on Wednesday. They presently have a $12.00 price objective on the stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 109.06% from the company’s previous close.
A number of other research firms have also commented on TXMD. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Thursday, November 24th. Jefferies Group set a $18.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research note on Tuesday, December 6th. Guggenheim reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, November 29th. Stifel Nicolaus lifted their price objective on TherapeuticsMD from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, December 6th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $10.50 price objective on shares of TherapeuticsMD in a research note on Sunday, December 4th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. TherapeuticsMD currently has a consensus rating of “Buy” and a consensus target price of $14.38.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 5.74 on Wednesday. The firm’s market capitalization is $1.13 billion. The stock’s 50 day moving average price is $6.05 and its 200-day moving average price is $6.77. TherapeuticsMD has a 12 month low of $4.39 and a 12 month high of $9.29.
WARNING: This piece was originally published by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright laws. The original version of this piece can be accessed at http://www.dailypolitical.com/2017/01/13/therapeuticsmd-inc-txmd-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Group LTD increased its stake in TherapeuticsMD by 2.9% in the third quarter. BlackRock Group LTD now owns 102,236 shares of the company’s stock worth $695,000 after buying an additional 2,861 shares during the period. Rhumbline Advisers increased its stake in TherapeuticsMD by 1.6% in the third quarter. Rhumbline Advisers now owns 159,694 shares of the company’s stock worth $1,088,000 after buying an additional 2,540 shares during the period. BlackRock Fund Advisors increased its stake in TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock worth $34,455,000 after buying an additional 426,991 shares during the period. BlackRock Inc. increased its stake in TherapeuticsMD by 7.1% in the third quarter. BlackRock Inc. now owns 16,303 shares of the company’s stock worth $111,000 after buying an additional 1,080 shares during the period. Finally, BlackRock Investment Management LLC increased its stake in TherapeuticsMD by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 569,885 shares of the company’s stock worth $3,881,000 after buying an additional 7,579 shares during the period.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.